Afuresertib hydrochloride is under clinical development by Laekna and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Afuresertib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Afuresertib hydrochloride overview
Afuresertib hydrochloride (GSK2110183, ASB-183) is under development for the treatment of locally advanced or metastatic HR positive/HER2 negative breast cancer, ovarian clear cell carcinoma, fallopian tube cancer, primary peritoneal cancer, metastatic castration resistant prostate cancer, triple-negative breast cancer, solid tumors, adenosquamous carcinoma or adenocarcinoma of the cervix, endometrial carcinoma with endometrioid, esophageal squamous cell carcinoma, metastatic non-small cell lung cancer (squamous cell carcinoma), metastatic HER2- gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. The drug candidate is administered through oral route in the form of tablet. It is a potent pan-AKT inhibitor which acts by targeting all three AKT isoforms AKT1, AKT2 and AKT3.
It was also under development for relapsed multiple myeloma, breast cancer, renal cell carcinoma, non-small cell lung cancer, colorectal cancer, melanoma, head and neck cancer, pancreatic cancer, bladder cancer, hepatocellular cancer, refractory multiple myeloma and Langerhans cell histiocytosis, hematological tumors including relapsed or refractory chronic lymphocytic leukemia (CLL).
Laekna overview
Laekna is a clinical-stage biotechnology company. It develops novel therapies for the treatment of cancer, liver fibrosis, and metabolic diseases. The company is developing its lead product candidate, LAE002 for the treatment of triple-negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), and resistant solid tumors. Its pipeline includes LAE001 to treat metastatic hormone-sensitive prostate cancer (mHSPC); and other drug candidates for cancer treatments. Laekna is also developing a pipeline product range that includes LAE104, LAE105, and LAE106 drug candidates for liver fibrosis treatment. The company was funded by OrbiMed Healthcare Fund, CS Capital, SCGC, GP Healthcare Capital, and Yanchuang Capital. It operates in China, Hong Kong, and the US. Laekna is headquartered in Shanghai, China.
For a complete picture of Afuresertib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
